

label containing the common or usual name of each active ingredient, namely, sulfadiazine and sulfathiazole; and, Section 502 (f) (2), the labeling of the repackaged *Desoxyn Hydrochloride tablets* bore no warnings against use in those pathological conditions where their use may be dangerous to health, and against unsafe dosage and methods and duration of administration.

DISPOSITION: May 4, 1951. Pleas of guilty having been entered, the court imposed a fine of \$300 against Defendant Garner, a fine of \$150 against Defendant Gill, and a fine of \$75 against Defendant Hartman.

3425. Misbranding of sulfadiazine tablets, Desoxyn Hydrochloride tablets, and thyroid tablets. U. S. v. The Sloan Drug Co., Theodore J. Schlonsky, and Harry Wolman. Pleas of guilty. Fine of \$300 against company, \$225 against Defendant Schlonsky, and \$150 against Defendant Wolman. (F. D. C. No. 30573. Sample Nos. 84423-K, 84424-K, 84427-K.)

INFORMATION FILED: Between April 20 and May 4, 1951, Southern District of Ohio, against The Sloan Drug Co., a corporation, Columbus, Ohio, and Theodore J. Schlonsky, secretary of the corporation, and Harry Wolman, pharmacist for the corporation.

INTERSTATE SHIPMENT: From the States of Indiana, Illinois, and New York, into the State of Ohio, of quantities of *sulfadiazine tablets*, *Desoxyn Hydrochloride tablets*, and *thyroid tablets*.

ALLEGED VIOLATION: On or about June 13, 15, and 20, 1950, while the drugs were being held for sale at The Sloan Drug Co. after shipment in interstate commerce, various quantities of the drugs were repacked and sold without a prescription, which acts resulted in the repackaged drugs being misbranded.

The Sloan Drug Co. and Theodore J. Schlonsky were charged with causing the acts of repacking and sale of the drugs involved in each of the three counts of the information; and, in addition, Harry Wolman was charged in two of the counts with causing such acts to be done in connection with the drugs involved in those counts.

NATURE OF CHARGE: Misbranding, Section 502 (b) (1), the repackaged *sulfadiazine tablets* and *Desoxyn Hydrochloride tablets* failed to bear labels containing the name and place of business of the manufacturer, packer, or distributor; Section 502 (b) (2), all of the repackaged drugs failed to bear labels containing a statement of the quantity of the contents; Section 502 (e) (1), the repackaged *sulfadiazine tablets* and *Desoxyn Hydrochloride tablets* failed to bear labels containing the common or usual names of the drugs; Section 502 (f) (1), the repackaged *Desoxyn Hydrochloride tablets* and *thyroid tablets* failed to bear labeling containing directions for use; and, Section 502 (f) (2), the repackaged *sulfadiazine tablets* and *Desoxyn Hydrochloride tablets* failed to bear labeling containing warnings against use in those pathological conditions where their use may be dangerous to health, and against unsafe dosage and methods and duration of administration.

DISPOSITION: May 4, 1951. Pleas of guilty having been entered, the court imposed a fine of \$300 against the corporation, a fine of \$225 against Defendant Schlonsky, and a fine of \$150 against Defendant Wolman.

3426. Misbranding of sulfathiazole tablets and Combisul tablets. U. S. v. The Poulston Drug Co. and Harry D. Poulston. Pleas of nolo contendere. Fine of \$100 against each defendant, plus costs. (F. D. C. No. 30043. Sample Nos. 52968-K, 72840-K, 84162-K, 84938-K, 84961-K.)